Todd Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Todd Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,098	Closed	-$202K	–	229
2021 Q2	$202K	Buy	+1,098	New	+$188K	﹤0.01%	215
2020 Q1	–	Sell	-2,117	Closed	-$229K	–	232
2019 Q4	$229K	Hold	2,117	–	–	0.01%	208
2019 Q3	$207K	Buy	+2,117	New	+$239K	0.01%	216

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Todd Asset Management's ALXN Position: Q3 2021 in Review

Todd Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,098 shares — an estimated $202K sold.

Todd Asset Management first reported a position in ALXN in Q3 2019 and held it in 3 quarters. The position peaked at $229K in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Todd Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Todd Asset Management sold 1,098 Alexion Pharmaceuticals shares in Q3 2021, an estimated $202K.
Todd Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 3 quarters.
Todd Asset Management's Alexion Pharmaceuticals position peaked at $229K in Q4 2019.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Todd Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.